Teikyo University School of Medicine, Department of Internal Medicine, 2-11-1 Kaga Itabashi-ku, Tokyo 173-8605, Japan.
Expert Opin Pharmacother. 2012 Apr;13(6):859-65. doi: 10.1517/14656566.2012.660525. Epub 2012 Feb 15.
Statins are currently the most effective drugs for lowering low-density lipoprotein cholesterol (LDL-C) and represent the first choice for treating hypercholesterolemia. Pitavastatin was launched as a new statin on the Japanese market in 2003, followed by Korea, Thailand, China, the United States and Europe. This review summarizes and evaluates new insights into pitavastatin, from clinical trials since 2010.
This article reviews studies that compare pitavastatin with various other statins: i) Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL): the PATROL Trial; ii) various Phase III clinical trials in Western countries; iii) The Comparison of Preventive Effect on Cardiovascular Events With Different Statins (CIRCLE) study; and iv) The Livalo Effectiveness and Safety (LIVES) Study Extension. Pitavastatin was found to have a similar LDL-C-lowering effect to other strong statins but also had a strong HDL-C-elevating effect and did not worsen glucose metabolism.
Pitavastatin has been launched in various countries around the world as a statin with potent LDL-C-lowering activity that is virtually unmetabolized by the cytochrome P450 family, with relatively few drug-drug interactions and no adverse effects on blood glucose. Pitavastatin thus appears well suited to long-term use.
他汀类药物目前是降低低密度脂蛋白胆固醇(LDL-C)最有效的药物,是治疗高胆固醇血症的首选药物。培伐他汀于 2003 年在日本上市,随后在韩国、泰国、中国、美国和欧洲上市。本文综述了 2010 年以来培伐他汀的临床试验,总结并评价了其新的研究进展。
本文综述了与其他他汀类药物进行比较的研究:i)培伐他汀、阿托伐他汀和瑞舒伐他汀安全性和疗效的随机头对头比较(LDL 的数量和质量):PATROL 试验;ii)西方国家的各种 III 期临床试验;iii)不同他汀类药物预防心血管事件的比较(CIRCLE)研究;iv)利伐他汀疗效和安全性(LIVES)研究的扩展。研究发现,培伐他汀降低 LDL-C 的作用与其他强效他汀类药物相似,但具有较强的升高高密度脂蛋白胆固醇的作用,且不会加重葡萄糖代谢异常。
培伐他汀作为一种他汀类药物已在全球多个国家上市,具有强大的 LDL-C 降低活性,几乎不被细胞色素 P450 家族代谢,药物相互作用相对较少,对血糖无不良影响。因此,培伐他汀似乎非常适合长期使用。